Zobrazení zdroje stránky Alfordfinnegan0362

0001) and TcPO<br /><br /> of &gt; 15% at the midfoot (35 of 41 [85.37%] vs 17 of 40 [42.50%]; P= .0001] and lower foot (37 of 41 [90.24%] vs 19 of 40 [47.50%]; P &lt; .0001). [https://www.selleckchem.com/products/meclofenamate-sodium.html https://www.selleckchem.com/products/meclofenamate-sodium.html] No patients with CLI underwent major amputation in group B, compared with 4 in group A (P= .0390). No significant difference was observed in relief from rest pain or &gt; 30% reduction in ulcer size among patients with CLI or in &gt; 50% improvement in pain-free walking distance among patients with severe claudication.<br /><br /> Intraarterial delivery of autologous BMSCs is safe and effective in the management of severe PAD.<br /><br />Intraarterial delivery of autologous BMSCs is safe and effective in the management of severe PAD.<br /><br /> To investigate the safety and effectiveness of primary conservative therapy for patients with symptomatic isolated mesenteric artery dissection (IMAD) with a severely compressed true lumen and/or a large dissecting aneurysm.<br /><br /> A total of 35 consecutive patients (all men; median age, 53 y) with symptomatic IMAD with a severely compressed true lumen and/or a large dissecting aneurysm but without intestinal necrosis or arterial rupture who were treated with primary conservative therapy between November 2018 and February 2020 were assessed. A severely compressed true lumen was defined as luminal stenosis &gt; 70%. A large dissecting aneurysm was defined as dissecting aneurysm diameter ≥ 1.5 times larger than the normal mesenteric artery diameter.<br /><br /> There was a strong positive relationship among abdominal pain, degree of luminal stenosis, and length of dissection (R= 0.811; P &lt; .001). Conservative treatment was successful in all patients. Abdominal pain was eliminated within 4.7 d ± 4.8 (range, 2-31 d) in all patients, within 3.6 d ± 1.2 (range, 2-6) in the 31 patients with minor or moderate abdominal pain,and within 13.3 d ± 11.9 (range, 6-31 d) in the 4 patients with severe abdominal pain. Complete or partial remodelingof the mesenteric artery was achieved in 6 (17.1%) and 29 (82.9%) patients, respectively, during 8.6 mo ± 4.3 of follow-up.<br /><br /> Primary conservative therapy can be used safely and effectively in patients with symptomatic IMAD with a severely compressed true lumen and/or a large dissecting aneurysm but without intestinal necrosis or arterial rupture.<br /><br />Primary conservative therapy can be used safely and effectively in patients with symptomatic IMAD with a severely compressed true lumen and/or a large dissecting aneurysm but without intestinal necrosis or arterial rupture.<br /><br /> To evaluate the feasibility and technical outcomes of retrograde access via occluded pedal arteries in endovascular treatment of critical limb ischemia (CLI) when the conventional antegrade approach fails.<br /><br /> One hundred fifty-one patients with CLI (age 69 y ± 10.5; 116 men) who were not surgical candidates and were treated via retrograde pedal access between January 2016 and January 2018 were evaluated retrospectively. Seventy patients in whom retrograde access was performed through occluded arteries constituted the occluded group, and 81 patients who were treated via retrograde access from patent arteries constituted the nonoccluded group. Pedal access success, lesion crossing success, angiographic success, overall technical success, and procedure-related complications were evaluated and compared between groups.<br /><br /> Pedal access success (74 of 78 vs 83 of 87 attempts; P= .873) and lesion crossing success (64 of 78 vs 77 of 87 lesions; P= .340) were comparable between subgroups. Angiographic success (54 of 78 vs 77 of 87 lesions; P= .012) and overall technical success (48 of 70 vs 72 of 81 patients; P= .004) rates were lower in the occluded group. Procedure-related complications were similar between groups (P= .096).<br /><br /> Retrograde pedal access from occluded pedal arteries is a feasible option when an antegrade approach fails in endovascular treatment of CLI. Although it has lower technical success, its use enables angiosome-directed therapy and has the potential to improve the outcomes of the procedure.<br /><br />Retrograde pedal access from occluded pedal arteries is a feasible option when an antegrade approach fails in endovascular treatment of CLI. Although it has lower technical success, its use enables angiosome-directed therapy and has the potential to improve the outcomes of the procedure.<br /><br /> To evaluate the safety and efficacy of prostatic artery embolization (PAE) in patients with recurrent lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) who underwent a previous transurethral resection of the prostate (TURP).<br /><br /> This retrospective study analyzed 15 of 19 patients who underwent PAE for recurrent LUTS after TURP between February 2014 and April 2019. The technical and clinical success rates and complications related to the procedure were recorded. International Prostate Symptom Score (IPSS), quality of life (QoL), and prostatic volume (PV) were evaluated at baseline and 3- and 12-mo follow-up.<br /><br /> The intervals from TURP to recurrent symptoms and from TURP to PAE were 4.3 y ± 3.2 and 5.6 y ± 3.8, respectively. Technical success was achieved in all patients. The clinical success rate for LUTS relief at 12 mo was 93.3% (14 of 15). IPSS significantly reduced from 22.5 ± 4.1 at baseline to 9.9 ± 4.9 at 12-mo follow-up, and QoL score improved from 4.7 ± 1.0 to 2.1 ± 1.1 (P &lt; .05 for both). There was a significant mean reduction of 26.6% in PV at 12 mo, improving from 100.7 cm<br /><br /> ± 38.5 to 73.9 cm<br /><br /> ± 29.4 (P &lt; .05). No severe complications were encountered.<br /><br /> PAE may be a safe and effective treatment option for the management of recurrent LUTS secondary to BPH in patients who have previously undergone TURP.<br /><br />PAE may be a safe and effective treatment option for the management of recurrent LUTS secondary to BPH in patients who have previously undergone TURP.<br /><br /> Several insights into obesity-osteoarthritis (OA) relationship have been recently highlighted. Adipolin and metrnl are new adipokines also secreted by chondrocytes. However, their role in OA, and obesity-OA interplay hasn't been elucidated. Therefore, this study was designed to investigate the circulating as well as synovial fluid (SF) levels of adipolin and metrnl in osteoarthritic-patients compared to non-osteoarthritic subjects, and to study their association with OA-severity, dyslipidemia and insulin resistance (IR).<br /><br /> Patients with osteoarthritis and obesity (n=30), and subjects with obesity not suffering OA (n=25) were enrolled in the current study. Circulating and SF-levels of adipolin, metrnl, and insulin, as well as SF-levels of matrix-metalloproteinase-13 (MMP-13) were measured by ELISA. Knee-radiographs using X-ray were done to determine OA-severity, and investigate its association with adipokines' levels.<br /><br /> Serum and SF-adipolin levels showed tendency to be lower in OA-patients compared to non-OA-subjects; serum 0.